B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 52, Issue 10, 2005, Pages 3168-3174

  Marks, Stephen D ^a   Patey, Sue ^a   Brogan, Paul A ^a   Hasson, Nathan ^a   Pilkington, Clarissa ^a   Woo, Patricia ^a   Tullus, Kjell ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; MEPACRINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; RITUXIMAB; SILDENAFIL;

ADOLESCENT; ANAPHYLAXIS; ARTHROPATHY; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DEPLETION THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GROWTH RETARDATION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOTHERAPY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LUNG HEMORRHAGE; MALE; MULTIPLE ORGAN FAILURE; OPEN STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RESPIRATORY DISTRESS; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 26844510846     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21351     Document Type: Article

References (33)

1. Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 1996;7:924-9.
2. Bogdanovic R, Nikolic V, Pasic S, Dimitrijevic J, Lipkovska-Markovic J, Eric-Marinkovic J, et al. Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol 2004;19:36-44.
3. Font J, Cervera R, Espinosa G, Pallares L, Ramos-Casals M, Jimenez S, et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998;57:456-9.
4. Glidden RS, Mantzouranis EC, Borel Y. Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients. Clin Immunol Immunopathol 1983;29: 196-210.
5. Marini R, Costallat LT. Young age at onset, renal involvement, and arterial hypertension are of adverse prognostic significance in juvenile systemic lupus erythematosus. Rev Rhum Engl Ed 1999; 66:303-9.
6. Walravens PA, Chase HP. The prognosis of childhood systemic lupus erythematosus. Am J Dis Child 1976;130:929-33.
7. Wang LC, Yang YH, Lu MY, Chiang BL. Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. J Microbiol Immunol Infect 2003;36:203-8.
8. Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998;160:51-9.
9. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999;169: 107-21.
10. Reininger L, Winkler TH, Kalberer CP, Jourdan M, Melchers F, Relink AG. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB x NZW)F1 mice. J Exp Med 1996;184:853-61.
11. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.
12. Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003;17:417-22.
13. Gorman C, Leandro M, Isenberg D. B cell depletion in autoimmune disease. Arthritis Res Ther 2003;5 Suppl 4:S17-21.
14. Hainsworth JD, Burris HA III, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD III, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000;95:3052-6.
15. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004;4: 398-402.
16. Ten Cate R, Smiers FJ, Bredius RG, Lankester AC, Suijlekom-Smit LW, Huizinga TW, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus [letter]. Rheumatology (Oxford) 2004;43:244.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
19. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
20. Marks SD, Pilkington C, Woo P, Dillon MJ. The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford) 2004;43:1186-9.
21. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996;55:756-60.
22. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
23. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
24. Saito B, Nakamaki T, Adachi D, Suzuki J, Tomoyasu S. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol 2004; 80:164-7.
25. Cheson BD. Rituximab: clinical development and future directions. Expert Opin Biol Ther 2002;2:97-110.
26. Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 1999;17:1962-3.
27. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-24.
28. Cameron JS. Lupus nephritis in childhood and adolescence. Pediatr Nephrol 1994;8:230-49.
29. Emre S, Bilge I, Sirin A, Kilicaslan I, Nayir A, Oktem F, et al. Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron 2001;87:118-26.
30. Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002;29:2635-42.
31. Khoo J, Pee S, Thevarajah B, Yap Y, Chin C. Lupus nephritis in children in Malaysia. J Paediatr Child Health 2005;41:31-5.
32. Yang LY, Chen WP, Lin CY. Lupus nephritis in children: a review of 167 patients. Pediatrics 1994;94:335-40.
33. Zappitelli M, Duffy C, Bernard C, Scuccimarri R, Watanabe DK, Kagan R, et al. Clinicopathological study of the WHO classification in childhood lupus nephritis. Pediatr Nephrol 2004;19:503-10.